Real-world patterns of chemotherapy and immunotherapy utilization at end of life in a large community oncology network.

22Background: End-of-life anti-neoplastic treatment does not improve quality of life nor prolong survival of advanced cancer patients. It is also not cost-effective. To-date, there has been little ...